Table 1 Cohort characteristics and biomarker values in the clinical validation.
Cohort | Controls (42) | AD (43) | Total (85) | p | |
|---|---|---|---|---|---|
Sex, M/F | 25/17 | 21/22 | 39/46 | 0.33 | |
M (SD) | Age, y | 61.7 (5) | 68.1 (6) | 64.9 (6) | < 0.001 |
M (SD) | MMSE | 27.2 (3) | 22.0 (5) | 24.6 (5) | < 0.001 |
n | 42 | 42 | 84 | ||
M (IQR) | CSF Tau (pg/mL) | 223 (117) | 615 (399) | 427 (395) | < 0.001 |
n | 42 | 43 | 85 | ||
M (IQR) | CSF P-tau (pg/mL) | 39 (15) | 89 (37) | 63 (36) | < 0.001 |
n | 41 | 43 | 84 | ||
M (IQR) | CSF Abeta 42 (pg/mL) | 1132 (308) | 658 (153) | 804 (475) | < 0.001 |
n | 42 | 43 | 85 |
